dc.contributor.author | Weller, A | |
dc.contributor.author | O'Brien, MER | |
dc.contributor.author | Ahmed, M | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Bhosle, J | |
dc.contributor.author | McDonald, F | |
dc.contributor.author | Yap, TA | |
dc.contributor.author | Du, Y | |
dc.contributor.author | Vlahos, I | |
dc.contributor.author | deSouza, NM | |
dc.date.accessioned | 2017-07-13T13:20:35Z | |
dc.date.issued | 2016-05-01 | |
dc.identifier.citation | European journal of cancer (Oxford, England : 1990), 2016, 59 pp. 65 - 78 | |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/693 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2016.02.017 | |
dc.description.abstract | Therapeutic options in locally advanced non-small cell lung cancer (NSCLC) have expanded in the past decade to include a palate of targeted interventions such as high dose targeted thermal ablations, radiotherapy and growing platform of antibody and small molecule therapies and immunotherapies. Although these therapies have varied mechanisms of action, they often induce changes in tumour architecture and microenvironment such that response is not always accompanied by early reduction in tumour mass, and evaluation by criteria other than size is needed to report more effectively on response. Functional imaging techniques, which probe the tumour and its microenvironment through novel positron emission tomography and magnetic resonance imaging techniques, offer more detailed insights into and quantitation of tumour response than is available on anatomical imaging alone. Use of these biomarkers, or other rational combinations as readouts of pathological response in NSCLC have potential to provide more accurate predictors of treatment outcomes. In this article, the robustness of the more commonly available positron emission tomography and magnetic resonance imaging biomarker indices is examined and the evidence for their application in NSCLC is reviewed. | |
dc.format | Print-Electronic | |
dc.format.extent | 65 - 78 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.subject | Humans | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Lung Neoplasms | |
dc.subject | Antineoplastic Agents | |
dc.subject | Radiopharmaceuticals | |
dc.subject | Observer Variation | |
dc.subject | Positron-Emission Tomography | |
dc.subject | Magnetic Resonance Imaging | |
dc.subject | Catheter Ablation | |
dc.subject | Treatment Outcome | |
dc.subject | Immunotherapy | |
dc.subject | Cell Proliferation | |
dc.subject | Cell Hypoxia | |
dc.subject | Forecasting | |
dc.subject | Molecular Targeted Therapy | |
dc.subject | Tumor Microenvironment | |
dc.subject | Multimodal Imaging | |
dc.subject | Biomarkers, Tumor | |
dc.subject | Positron Emission Tomography Computed Tomography | |
dc.title | Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-02-18 | |
rioxxterms.versionofrecord | 10.1016/j.ejca.2016.02.017 | |
rioxxterms.licenseref.startdate | 2016-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of cancer (Oxford, England : 1990) | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Lung Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Lung Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 59 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine Drug Development Unit (de Bono) | |
icr.researchteam | Thoracic Oncology | |
icr.researchteam | Treatment of thoracic tumours | |
icr.researchteam | Lung Radiotherapy | |
icr.researchteam | Magnetic Resonance | |
dc.contributor.icrauthor | Weller, Alexander | |
dc.contributor.icrauthor | deSouza, Nandita | |